Omeros Corporation (OMER)

[umiak]

Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA

1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.

Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.

The FDA has set the Prescription Drug User Fee Act action date on July 17.